Anti-SARM1 antibody [EPR24834-80],Abcam,AB309195
What is this antibody validated in? Anti-SARM1 antibody [EPR24834-80] (ab309195) is a rabbit recombinant monoclonal antibody and is validated for use in Western Blot (WB), Immunoprecipitation (IP), Immunohistochemistry (IHC-P), Immunohistochemistry (IHC-Fr), Immunocytochemistry/immunofluorescence (ICC/IF), Multiplex IHC (mIHC) in Human, Mouse, Rat samples. Trial sizes available! Test your antibody or perform pre-screening before committing to a larger quantity. Sold in 10µl. Discover our selection of trial-size antibodies. Specificity confirmed The specificity of Anti-SARM1 antibody [EPR24834-80] (ab309195) has been confirmed by Western blot testing in Sarm1 Knockout Mouse brain samples. Other related products We have a range of other formats of antibody clone [EPR24834-80] also available for your convenience: ab309195, Carrier free - ab309196 Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .
Host
Rabbit
Reactivity
Rat, Human, Mouse
Application
IP, mIHC, IHC-P, IHC-Fr, ICC/IF, WB
Platform ID
BAB839108972
Abcam
Contact
Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215
Email:
Specifications
Scientific Background
Target data NAD(+) hydrolase, which plays a key role in axonal degeneration following injury by regulating NAD(+) metabolism (PubMed : 25818290, PubMed : 26686637, PubMed : 27735788, PubMed : 32312889). Acts as a negative regulator of MYD88- and TRIF-dependent toll-like receptor signaling pathway by promoting Wallerian degeneration, an injury-induced form of programmed subcellular death which involves degeneration of an axon distal to the injury site (PubMed : 21555464, PubMed : 22678360, PubMed : 25818290, PubMed : 26423149, PubMed : 26686637). Wallerian degeneration is triggered by NAD(+) depletion : in response to injury, SARM1 is activated and catalyzes cleavage of NAD(+) into ADP-D-ribose (ADPR), cyclic ADPR (cADPR) and nicotinamide; NAD(+) cleavage promoting cytoskeletal degradation and axon destruction (PubMed : 28334607). Also able to hydrolyze NADP(+), but not other NAD(+)-related molecules (By similarity). Can activate neuronal cell death in response to stress (PubMed : 19587044). Regulates dendritic arborization through the MAPK4-JNK pathway (PubMed : 17724133, PubMed : 21555464). Involved in innate immune response : inhibits both TICAM1/TRIF- and MYD88-dependent activation of JUN/AP-1, TRIF-dependent activation of NF-kappa-B and IRF3, and the phosphorylation of MAPK14/p38 (PubMed : 21555464). See full target information Sarm1
Category Paths
- Products>Primary Antibodies>Monoclonal Antibodies
- Products>Primary Antibodies>IHC Antibodies
- Products>Primary Antibodies>Recombinant Antibodies
- Products>Trial Size Antibodies
Please provide the required information below so that we can quickly source your products.